AUS
NZ
UK
CA
USA
IND
Highlights
- STERIS holds an average “Moderate Buy” rating from six analysts.
- Institutional investors control 94.69% of the company’s stock.
- STERIS announced a quarterly dividend with a yield of 1.05%.
STERIS plc, a recognized player in the NYSE Healthcare Stocks sector, is making waves with its strong market positioning and solid financial health. With an evolving product portfolio in infection prevention and medical equipment, STERIS continues to attract attention from analysts and institutional investors alike, reflecting confidence in its role within the healthcare industry. As the company adapts to changing market dynamics, it remains a key focus for those tracking trends in healthcare innovation and investment.
Analyst Ratings and Target Price for STERIS plc (NYSE:STE)
STERIS plc, has garnered an average rating of "Moderate Buy" from six analysts covering the company. This consensus includes two analysts with a "hold" rating and four issuing a "buy" rating. The average 12-month target price for the stock is set at $253, indicating a moderate upside from its current price levels. Analyst attention has been focused on STERIS' performance within the medical equipment sector, where it faces both competition and market fluctuations.
Recent analyst reports provide insights into the company’s future potential. For instance, Needham & Company LLC reiterated a "hold" rating on November 8, while JMP Securities issued a "market outperform" rating and set a price target of $265 on November 18. Additionally, Piper Sandler upgraded the stock from "neutral" to "overweight," raising their target price to $260.
Institutional Investor Activity
Institutional investors continue to hold a dominant share of STERIS stock, controlling 94.69% of the company’s shares. A number of hedge funds and institutional players have recently adjusted their holdings in STERIS, reflecting continued interest in the medical equipment provider. Notable moves include Quent Capital LLC, which increased its position by 112.7%, and Cetera Investment Advisers, which raised its stake by 215.1%. These actions highlight strong institutional confidence in STERIS, despite its relatively high valuation compared to its sector peers.
Stock Performance and Financials
STERIS stock opened at $217.47 on the latest trading day, with a 52-week range from $195.47 to $248.24. The company has shown consistent performance, with a market capitalization of $21.47 billion, a P/E ratio of 49.65, and a beta of 0.85, indicating lower volatility compared to the broader market. STERIS has maintained a solid financial position, with a current ratio of 2.41 and a quick ratio of 1.55, both suggesting strong liquidity.
The company’s most recent earnings report, posted on November 6, showed EPS of $2.14 for the quarter, slightly surpassing analysts' estimates of $2.12. Revenue for the quarter was $1.33 billion, a 7.3% year-over-year increase. Despite some challenges in its core segments, STERIS remains resilient, maintaining an 8.02% net margin and a return on equity of 13.78%.
Dividend Announcement
In addition to its strong financial performance, STERIS declared a quarterly dividend of $0.57 per share, payable on December 19 to stockholders of record as of November 19. This dividend represents a yield of 1.05%, with a payout ratio of 52.05%. Dividends are a key factor for institutional investors, further emphasizing the company's commitment to rewarding shareholders.
STERIS plc, continues to demonstrate its strength in the medical equipment and infection prevention sectors. With strong institutional backing, positive analyst sentiment, and consistent financial performance, the company appears well-positioned for the future. While analysts remain cautious with a "Moderate Buy" consensus, the overall outlook for STERIS remains favorable, supported by robust demand in its various market segments. As STERIS moves forward, its focus on innovation and operational excellence will likely play a significant role in shaping its long-term trajectory.
